| Metformin + saxagliptin for type 2 diabetes. | |
| | |
MedLine Citation:
|
PMID: 22149373 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Introduction: Metformin is considered as the first-line drug therapy for the management of type 2 diabetes. Dipeptidyl peptidase-4 (DPP-4) inhibitors, by promoting insulin secretion and reducing glucagon secretion in a glucose-dependent manner, offer new opportunities for oral therapy after failure of metformin. Areas covered: An updated review of the literature demonstrates that saxagliptin, a DPP-4 inhibitor, and metformin may be administered together, separately or in fixed-dose combination (FDC), either as saxagliptin added to metformin or as initial combination in drug-naive patients. Both compounds exert complementary pharmacodynamic actions leading to better improvement in blood glucose control (fasting plasma glucose, postprandial glucose, HbA1c) than either compound separately. Adding saxagliptin to metformin monthotherapy results in a consistent, sustained and safe reduction in HbA1c levels. Tolerance is excellent without hypoglycemia or weight gain. Expert opinion: The combination saxaglitpin plus metformin may be used as first-line or second-line therapy in the management of type 2 diabetes, especially as a valuable alternative to the classical metformin-sulfonylurea combination. |
| | |
Authors:
|
André J Scheen |
Related Documents
:
|
3451413 - Fasting plasma magnesium concentration and its relation to control in diabetic nigerians. 1519313 - The influence of thymus extracts on the chemotaxis of polymorphonuclear neutrophils (pm... 21626103 - Influence of insulin on glutamine synthetase in the müller glial cells of retina. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 13 ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2011-12-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 139-46 Citation Subset: IM |
Affiliation:
|
University of Liège, Division of Diabetes, Nutrition and Metabolic Disorders, and Division of Clinical Pharmacology, Department of Medicine , CHU Sart Tilman (B35), B-4000 Liege 1 , Belgium +32 4 3667238 ; +32 4 3667068 ; andre.scheen @ chu.ulg.ac.be. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Oxaliplatin : a review of approved uses.
Next Document: Pharyngeal motor evoked potentials elicited by transcranial electrical stimulation for intraoperativ...